Epitope-specific down-regulation of anti-allergen antibodies following injection of allergen-antibody complexes in hypersensitive patients.
Administration to allergic patients of complexes made of allergen and anti-allergen antibodies results in a reduction in the levels of specific IgE and IgG antibodies that is limited to antibodies present in the complexes. The epitope-specific nature of this reduction is demonstrated by taking advantage of the cross-reactivity between Der p I and Der f I. In addition, an increased production of anti-idiotypic antibodies is demonstrated. As such treatment significantly improves patients with allergic asthma or atopic dermatitis, it may represent a valuable alternative to conventional immunotherapy.